Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

Beatrix Stelte-Ludwig, Tibor Schomber, Raquel Izumi, Harvey Wong, Melanie M Frigault, Anne-Sophie Rebstock, Sebastian Ludwig, Arushi Mithal, Amy J Johnson, Ahmed Hamdy

Blood (2023) 142 (Supplement 1): 1435.

https://doi.org/10.1182/blood-2023-182260

Published: 2023

Journal Articles

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Ritul Sharma, Melanie M Frigault, Amy J Johnson, Raquel Izumi, Ahmed Hamdy, Joseph Birkett, Beatrix Stelte-Ludwig, Luke Maese, Norman J. Lacayo, Aru Narendran

Blood (2023) 142 (Supplement 1): 4293.

https://doi.org/10.1182/blood-2023-180567

Published: 2023

Journal Articles

Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model

Tibor Schomber, Beatrix Stelte-Ludwig, Anne-Sophie Rebstock, Oliver v Ahsen, Amy J Johnson, Raquel Izumi, Ahmed Hamdy

Blood (2023) 142 (Supplement 1): 2809.

https://doi.org/10.1182/blood-2023-182185

Published: 2023

Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Blood (2022) 140 (Supplement 1): 9454–9456.

https://doi.org/10.1182/blood-2022-167651

Published: 2022

Journal Articles

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

Beatrix Stelte-Ludwig, George Clemens, Tibor Schomber, Melanie M. Frigault, Amy J. Johnson, Hans-Georg Lerchen, Raquel Izumi, Ahmed Hamdy

Blood (2022) 140 (Supplement 1): 5955–5956.

https://doi.org/10.1182/blood-2022-167556

Published: 2022

Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran

Blood (2022) 140 (Supplement 1): 10685–10686.

https://doi.org/10.1182/blood-2022-169917

Published: 2022

Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella

Blood (2021) 138 (Supplement 1): 270.

https://doi.org/10.1182/blood-2021-153812

Published: 2021

Journal Articles

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Melanie M. Frigault, Harvey Wong, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy

Blood (2021) 138 (Supplement 1): 1192.

https://doi.org/10.1182/blood-2021-150917

Published: 2021

Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 3918.

https://doi.org/10.1182/blood-2019-127464

Published: 2019

Journal Articles

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Ishwarya Murali, PhD BS, Siddha Kasar, PhD, Emily M. McWilliams, PhD, Gilad Itchaki, Svitlana Tyekucheva, PhD, Dimitri Livitz, BS, Ignaty Leshchiner, PhD, Shuai Dong, PhD, Stacey M. Fernandes, BS, Gad Getz, PhD, Amy J. Johnson, PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 587.

https://doi.org/10.1182/blood-2018-99-115304

Published: 2018

Journal Articles

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Joshua J. Rusbuldt, MA, Andressa A. Smith, PhD, Sriram Balasubramanian, Gary Borzillo, PhD, Amy J. Johnson, PhD, Diana Alvarez Arias, PhD

Blood (2018) 132 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2018-99-114622

Published: 2018

Journal Articles

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

Sean D. Reiff, Elizabeth M. Muhowski, Daphne Guinn, Amy Lehman, Catherine A. Fabian, Carolyn Cheney, Rose Mantel, Lisa Smith, Amy J. Johnson, Wendy B. Young, Adam R. Johnson, Lichuan Liu, John C. Byrd, Jennifer A. Woyach

Blood (2018) 132 (10): 1039–1049.

https://doi.org/10.1182/blood-2017-10-809020

Published: 2018

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Might broader be better?

Amy J. Johnson

Blood (2017) 130 (3): 239–240.

https://doi.org/10.1182/blood-2017-03-770206

Published: 2017

Journal Articles

NF-κB p50 ( nfkb1 ) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

Timothy L. Chen, Minh Tran, Aparna Lakshmanan, Bonnie K. Harrington, Nikhil Gupta, Virginia M. Goettl, Amy M. Lehman, Stephen Trudeau, David M. Lucas, Amy J. Johnson, John C. Byrd, Erin Hertlein

Blood (2017) 130 (3): 376–379.

https://doi.org/10.1182/blood-2017-01-761130

Published: 2017

Includes: Supplemental data

Journal Articles

Targeting BTK through microRNA in chronic lymphocytic leukemia

Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, Chaomei Liu, Lisa L. Smith, Rose Mantel, Sean Reiff, Dalia El-Gamal, Karilyn Larkin, Amy J. Johnson, Rosa Lapalombella, Amy Lehman, William Plunkett, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Blood (2016) 128 (26): 3101–3112.

https://doi.org/10.1182/blood-2016-07-727750

Published: 2016

Includes: Supplemental data

Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 1259.

https://doi.org/10.1182/blood.V128.22.1259.1259

Published: 2016

Journal Articles

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Fabienne McClanahan, MD PhD, Sean D. Reiff, Daphne Guinn, PhD, Minh Tran, Larry Beaver, Samantha McWorther, Rose Mantel, Lisa L. Smith, MS, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 352.

https://doi.org/10.1182/blood.V128.22.352.352

Published: 2016

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 3232.

https://doi.org/10.1182/blood.V128.22.3232.3232

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

NARROW

Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Might broader be better?

NF-κB p50 ( nfkb1 ) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

Targeting BTK through microRNA in chronic lymphocytic leukemia

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only